The necessity of gastric mucosal biopsy in dyspeptic patients with normal upper endoscopy in Modarres hospital 2017-2018 by Talaie, Ramin et al.
                                                                                                                           Novelty in Biomedicine 




The necessity of gastric mucosal biopsy in dyspeptic patients with 
normal upper endoscopy in Modarres hospital 2017-2018 
 
 
Ramin Talaie1, Mina Nickpour1*, Roham Gholami1 
 
1 Department of Internal medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran 
 
Received: 13 October, 2019; Accepted: 08 March, 2020 
Abstract 
Background: Considering the diagnostic and therapeutic costs of patients with dyspepsia and the importance of 
diagnosis during gastrointestinal malignancies, in this study, we investigated the necessity of gastric mucosal 
biopsy in dyspeptic patients with normal upper endoscopy in Modarres hospital and their 6 months follow up. 
We studied their endoscopic biopsies changes and some of the involved risk factors this duration. 
Materials and Methods: In this clinical trial study, 115 patients with dyspepsia, were referred from 
gastroenterology clinic of Modarres hospital during 2017-2018, were evaluated. Patients were enrolled in a study 
that did not have any ulcer and mass or deep mucosal lesion in the early endoscopy Surface erosions were no 
exception and could be included. Five biopsy samples were obtained from different stomach sites. After the 
pathology results, the patients who had malignancy reports, excluded from the study and other patients were 
treated with anti-acid drugs and, if necessary, eradicated Helicobacter pylori. After 6 months, they were again 
subjected to endoscopy and biopsies were taken. Data were analyzed by SPSS software version 22. 
Results: The rate of Helicobacter pylori in patients with endoscopic dyspepsia without mucosal lesions after 
6 months of treatment was reduced compared to pre-treatment p<0.05, 20.9% vs 12.2%. The severity of chronic 
gastritis mild to moderate in patients with endoscopic dyspepsia without mucosal lesions after 6 months of 
treatment was reduced compared to pre-treatment p<0.05, 89.6% vs 80%. There was a significant difference 
between metaplasia in patients with endoscopic dyspepsia without mucosal lesions before and 6 months after 
treatment p<0.05, 33%, vs 20%. Female gender, negative family history of GI cancer and not using alcohol 
were factors that significantly improved the results of biopsy chronic gastritis/ H. pylori /metaplasia after 6 
months. 
Conclusion: Regarding the reduction in the severity of chronic gastritis, Helicobacter pylori and metaplasia in 
this group of patients after 6 months of treatment, it is recommended that refraining from unnecessary follow-up 
and biopsy and imposing cost to the patient and the medical system and be limited to high-risk groups. 
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Introduction 
Dyspepsia is one of the most common complaints in 
clinical practice. Dyspepsia is generally defined as the 
recurrent epigastric pain and heartburn in conjunction 
with the feeling of reflux with or without bloating, 
nausea, and vomiting1-4. Dyspepsia is a prevalent 
symptom and can be caused by various factors 
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including: peptic ulcer disease, gastro-esophageal 
reflux disease (GERD), and malignancy. Dyspepsia is 
not along with a special symptom in some common 
cases and seems to be functional5. Functional 
dyspepsia is divided in to 4 classes in terms of the 
predominant symptoms: ulcer like, dysmotility like, 
GERD like and mixed type. In accordance with the 
latest Rome diagnostic criteria, four complaints 
among the above symptoms and complaints have been 
set to be the bases of diagnosis and division of 
dyspepsia, including: feeling tightness after meals, 
early satiety, abdominal pain and heartburn. Criteria 
fulfilled for the last 3 months with symptom onset at 
least 6 months prior to diagnosis6. 
Dyspepsia is a common public problem. A literature 
review on various studies regarding the prevalence of 
dyspepsia in Europe has shown an incidence rate of 
19-41%7. Another study in the United States with 
more limited diagnostic criteria indicated a 13% of 
incidence of this complication8. Sixty percent of 
patients referred to and examined for dyspepsia have 
no specific diseases like peptic ulcer, GERD and 
gastric cancer. Rather they are diagnosed with 
functional dyspepsia9. Helicobacter pylori (H. pylori) 
is an important bacterium which is well-known to be 
associated with duodenal or stomach ulcer, gastric 
malignancy and mucosa associated lympgoid tissue 
(MALT)10,11. 
Studies have shown that the highest delay time was 
related to the onset of GI symptoms until performing 
endoscopy at Iran, the highest delay was related to 
patients who were referred with a symptom of 
dyspepsia12,13. 
It is estimated that 25 to 40% of adults experience 
dyspeptic symptoms at least once in their lifetime. H. 
pylori is the most common cause of organic dyspepsia, 
and the majority of patients are classified as non-ulcer 
or functional dyspepsia, which is caused by a 
combination of motor disorders, visceral 
hypersensitivity, and non-adaptive psychological 
responses manifesting as gastrointestinal 
symptoms14,15. Moreover, H. pylori causes 
inflammation in the oxyntic cells and induced atrophic 
mucus, hence reducing the acid that itself a potential 
factor for cancer16,17. Due to the high incidence, rate 
and variety of causative agents, clinical evaluation and 
care of this discomfort have created a huge economic 
burden for different communities. 
Empirical treatment approaches with acid reducing 
agents or H. pylori treatment have been effective in 
reducing endoscopy rate and reducing treatment costs, 
however endoscopy as a reliable way to reject the 
existence of gastric cancer, especially among patients 
who are having risk factors. Besides, about 30% of 
cases with normal endoscopic findings biopsies have 
abnormal patholic findings in reendoscopy. 
Furthermore, sometimes the blind sample that were 
taken from a regions may not be involve, which in this 
cases is reported as false negative18. At present, 
according to the AGA guideline, among patients with 
dyspepsia with a normal appearance of endoscopy with 
a strong recommendation and a very low quality of 
evidence, biopsy is advised not to be performed. On the 
other hand, sufficient evidence and desirable 
indications are not well specified for repeating 
endoscopy for follow-up among patients with 
dyspepsia20. 
Intestinal metaplasia has also been reported among 6 to 
57% of the patients with normal gastro-esophageal 
junction in the upper endoscopy. Its ability to return to 
normal state was observed in the study by Goldstein. In 
this study, during 3-years follow up period, only 7% of 
metaplasia remained stable19. Taking into account this 
important issue and contradictory recommendations 
and findings, the researchers in this study examined the 
necessity of biopsy in upper endoscopy without 
mucosal lesions among patients with dyspepsia 
complaints and the necessity for follow up and the role 
of some of risk factors that effect on this changes19. 
Methods 
After obtaining the necessary permissions for the 
implementation of the study ethic code: 
IR.SBMU.MSP.REC.1396.666, the study was carried 
out using the clinical trial method. This clinical trial 
study was performed on 115 patients the sample size 
was calculated based on Goldstein study from his 
formula19. 
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] 
With dyspepsia who referred to the gastroenterology 
clinic of Modarres hospital diagnosis of dyspepsia was 
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based on patient complaints, Rome III and had 
indications of treatment in addition to absence the 
study exclusion criteria. The patients were placed 
under upper endoscopy and entered the study in case 
of the absence of clear and distinct mucosal lesions. In 
case of any deep lesion, mass, or ulcer, the patients 
were excluded from the study surface erosion was not 
an indication of exclusion. The study exclusion 
criteria included: having specific mucosal lesions, 
ulcers, mass, history of gastrointestinal malignancies, 
patients with a history of gastrointestinal and 
abdominal surgery, history of cardiovascular and 
pulmonary diseases patients with history of 
cardiovascular and pulmonary problems that were 
controlled by confirmation of cardiology or 
pulmonology consulting, were not exclusion criteria. 
Patients with bleeding disorder Platelets under 50000 
and PTT above 50 , having a history of warfarin or any 
other anti-coagulant use, high-risk patients for 
sedation or anesthesia, patients with a history of 
allergy to anesthetics drug and pregnancy Any of the 
above is the criterion for exclusion from the study. 
The informed consent was received from the patients 
and sufficient explanations on the diagnosis and 
treatment were provided to them. Then, the 
questionnaire for the evaluation of variables was 
completed and endoscopy was done for dyspeptic 
patients and biopsy was taken by a gastroenterologist 
five biopsy samples from random areas of small and 
large gastric curvature and peri-pyloric zone. The 
samples then were sent to the pathology department of 
Modarres hospital anonymously with a code assigned 
to the sample for histopathologic diagnosis and H. 
pylori examination single blind. Then, the medicines 
were required for improving dyspepsia symptoms, 
were prescribed for the patients including anti-acid, 
antihistamine, PPI, H. pylori eradication drugs in case 
of confirmation of infection. The patients were 
followed up monthly through phone call for general 
and gastrointestinal symptoms and were re-visited in 
case who were unimprovement or intensification of 
symptoms. After the end of the H. pylori treatment 
period, eradication was proven with UBT urease 
breath test or stool antigen. In case of reporting 
dysplasia or malignancy at the pathology stage, they 
were excluded from the study were referred to a 
surgeon or an oncologist; of 115 patients in the present 
study, there was no report of a dysplastic pathology or 
malignancy in the first pathology. Hence, the study 
continued with two groups of normal pathology and 
non-malignant pathology including metaplasia, chronic 
gastritis, and H. pylori infection. In the next step, the 
upper endoscopy was done at the same center Modarres 
hospital for follow up after nearly six months and the 
same pathologist reviewed the biopsies. The objective 
was to evaluate the patient's pathology changes during 
the 6-month follow-up period. The present study, was 
carried out aiming to investigate the effects of some 
variables that may be effect biopsies changes; including 
age, gender, body mass index BMI, duration of 
suffering from dyspepsia, family history of 
gastrointestinal malignancies, history of previously H. 
pylori infection, history of smoking and alcohol use, 
history of using drugs like steroids, ASA, nonsteroidal 
anti-inflammatory drugs NSAIDs, bisphosphonates and 
long-term antibiotics. On pathological changes 
pathology of metaplasia, gastritis and H. pylori 
infection in any endoscopy without mucosal lesions 
during treatment of dyspepsia in the next 6-month 
endoscopy surveyed. 
The gathered data were analyzed by SPSS V22. 
Therefore, to compare qualitative variables in two and 
three group Chi-square or Fisher exact test was used. In 
addition, Wilcoxon test was used for comparison before 
and 6 months after treatment (p<0.05 was considered 
significant). 
Results 
In this study, 115 patients with dyspepsia who referred 
to the gastroenterology clinic of Modarres hospital 
during the year 2017-2018 who had criteria for entering 
the study and who did not have definite mucosal 
lesions, ulcer and mass in upper endoscopy ,were 
entered. 
The age of the patients was between 23-85 years old 
with an average and standard deviation of 48.25±14.23 
years. A total of 51.3% (n=59) of patients were female. 
Body mass index in 62 patients (53.9%) was normal 
(<25), 37.4% (n=43) was overweight 25-30, 9 patients 
(7.8%) was obesity class 1 obesity BMI: 30-30 and 1 
patient (0.9%) was obesity class 2 BMI: 40-35. The 
duration of dyspepsia in 19 (16.5%) patients was less 
than 6 months, in 32 (27.8%) patients was between 6 
months to 1 year, in 38 (33%) patients was between 1-
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two year and in 26 (22.6%) was more than 2 years old. 
Ten patients (8.7%) had familial history of 
gastrointestinal malignancies. In 36 (31.3%) patients 
had a history of Helicobacter pylori. In 36 patients 
(31.3%) had a history of smoking. In 12 (10.4%) 
patients had a history of smoking. In 28 (24.3%) 
patients had history of using NSAIDs, in 16 (14%) 
patients had history of using aspirin, 6 (5.2%) patients 
had history of using alendronate and 1 (0.9%) patients 
had history of using corticosteroid. 
There was a significant difference between the 
severity of chronic gastritis in patients with 
endoscopic mucosal dyspepsia before and 6 months 
after treatment (p<0.05). The severity of chronic 
gastritis in patients with endoscopic mucosal 
dyspepsia after 6 months of treatment was reduced 
compared to pre-treatment (Table 1). 
There was a significant difference between the 
Helicobacter pylori in patients with endoscopic 
mucosal dyspepsia before and 6 months after 
treatment (p<0.05). The Helicobacter pylori in 
patients with endoscopic mucosal dyspepsia after 6 
months of treatment was reduced compared to pre-
treatment (Table 2). 
There was a significant difference between the 
metaplasia in patients with endoscopic mucosal 
dyspepsia before and 6 months after treatment 
(p<0.05). The metaplasia in patients with endoscopic 
mucosal dyspepsia after 6 months of treatment was 
reduced compared to pre-treatment (Table 3). 
Female, negative family history of gastrointestinal 
malignancies, negative history of alcohol abuse had a 
significant effect on the reduction of chronic gastritis 
after 6 months of treatment (p<0.05), but age, BMI, 
duration of dissection, previous history of Helicobacter 
pylori, history of smoking, and history of drug use had 
not significant effect on the downward trend of the 
severity of chronic gastritis after 6 months of treatment 
(Table 4). 
Female, duration of dyspepsia under 1 year of age, 
negative family history of gastrointestinal 
malignancies, negative history of Helicobacter pylori, 
negative history of smoking and alcohol, and negative 
history of drug use had significant effect on the 
decreasing rate of Helicobacter pylori after 6 treatment 
was affected (p<0.05). However, age and BMI had not 
significant effect on the downward trend of 
Helicobacter pylori after 6 months of treatment (Table 
5). 
Female, BMI under 25, duration of dyspnea under 1 
year of age, negative family history of gastrointestinal 
malignancies, negative history of Helicobacter pylori, 
negative history of smoking and alcohol, and negative 
history of drug use in patients on metaplasia was 
effective after 6 months of treatment (p<0.05). 
However, the patient's age did not effect on the  
Table 1: Comparison of severity of chronic gastritis in patients with dyspepsia with endoscopic mucosal lesions before 




No Mild Moderate 
Before 12 (10.4%) 79 (68.7%) 24 (20.9%) 
<0.001 
After 23 (20%) 80 (69.6%) 12 (10.4%) 
 
 Table 2: Comparison of Helicobacter pylori in patients with dyspepsia with endoscopic mucosal lesions before and 6 





Before 91 (79.1%) 24 (20.9%) 
0.018 
After 101 (87.8%) 14 (12.2%) 
 
 Table 3: Comparison of metaplasia pylori in patients with dyspepsia with endoscopic mucosal lesions before and 6 





Before 77 (67%) 38 (33%) 
0.002 
After 90 (80%) 23 (20%) 
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Table 4: Comparison of the severity of chronic gastritis in patients with endoscopic dyspepsia without mucosal lesions 
before and 6 months after treatment based on age, sex, BMI, duration of dyspnea, family history of gastrointestinal 






No Mild Moderate 
age (year) 
<50 
Before 10 (16.9%) 36 (61%) 13 (22%) 
0.007 
After 15 (25.4%) 39 (66.1%) 5 (8.5%) 
50=< 
Before 2 (3.6%) 43 (76.8%) 11 (19.6%) 
0.002 
After 8 (14.3%) 41 (73.2%) 7 (12.5%) 
Sex 
Male 
Before 7 (12.5%) 38 (67.9%) 11 (19.6%) 
0.058 
After 10 (17.9%) 38 (67.9%) 8 (14.3%) 
Female 
Before 5 (8.5%) 41 (69.5%) 13 (22%) 
<0.001 
After 13 (22%) 42 (71.2%) 4 (6.8%) 
BMI 
<=25 
Before 39 (66.1%) 15 (25.4%) 5 (8.5%) 
0.002 
After 40 (67.8%) 8 (13.6%) 11 (18.6%) 
25< 
Before 40 (71.4%) 9 (16.1%) 7 (12.5%) 
0.013 
After 40 (71.4%) 4 (7.1%) 12 (21.4%) 
duration of dyspepsia 
(years) 
<=1 
Before 34 (66.7%) 10 (19.6%) 7 (13.7%) 
0.005 
After 32 (62.7%) 5 (9.8%) 14 (27.5%) 
1< 
Before 45 (70.3%) 14 (21.9%) 5 (7.8%) 
0.005 
After 48 (75%) 7 (10.9%) 10 (16.9%) 




Before 0 (0%) 8 (80%) 2 (20%) 
0.317 
After 1 (10%) 8 (80%) 1 (10%) 
No 
Before 12 (11.4%) 71 (67.6%) 22 (21%) 
<0.001 
After 22 (21%) 72 (68.6%) 11 (10.5%) 
previous history of 
Helicobacter pylori 
Yes 
Before 2 (5.6%) 26 (72.2%) 8 (22.2%) 
0.007 
After 6 (16.7%) 27 (75%) 3 (8.3%) 
No 
Before 10 (12.7%) 53 (67.1%) 16 (20.3%) 
0.003 
After 17 (21.5%) 53 (67.1%) 9 (11.4%) 
history of smoking 
 
Yes 
Before 4 (11.1%) 25 (69.4%) 7 (19.4%) 
0.034 
After 9 (25%) 21 (58.3%) 6 (16.7%) 
No 
Before 8 (10.1%) 54 (68.4%) 17 (21.5%) 
0.001 
After 14 (17.7%) 59 (74.7%) 6 (7.6%) 
history of alcohol 
Yes 
Before 0 (0%) 9 (75%) 3 (25%) 
0.083 
After 2 (16.7%) 8 (66.7%) 2 (16.7%) 
No 
Before 12 (11.7%) 70 (68%) 21 (20.4%) 
<0.001 
After 21 (20.4%) 72 (69.9%) 10 (9.7%) 
history of drug* 
 
Yes 
Before 8 (12.5%) 44 (68.8%) 12 (18.8%) 
0.005 
After 16 (25%) 41 (64.1%) 7 (10.9%) 
No 
Before 4 (7.8%) 35 (68.6%) 12 (23.5%) 
0.004 
After 7 (13.7%) 39 (76.5%) 5 (9.8%) 
* The above-mentioned drugs. 
 
downward trend of metaplasia after 6 months of 
treatment (Table 6). 
Discussion 
Regarding the most important findings of the present 
study, the severity of chronic gastritis and the H. 
pylori and metaplasia rates, among dyspeptic patients 
without mucosal lesions in upper endoscopy, 
decreased in 6-month follow-up treatment in 
endoscopy biopsies compared to pre-treatment 
endoscopy biopsies. 
In addition, the H. pylori rate among dyspeptic patients 
with normal endoscopy decreased after 6 months of 
treatment compared to before treatment (p<0.05), 
20.9% vs 12.2%. The severity of chronic gastritis mild 
and moderate among dyspeptic patients without 
mucosal lesions decreased after 6 months of treatment 
compared to before treatment (p<0.05) 89.6% vs 80%. 
There was a difference in metaplasia rates among 
dyspeptic patients without mucosal lesions before and 
6 months after treatment (p<0.05) 33% vs 20%. Gender 
women, duration of dyspepsia below one year, negative  
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Table 5: Comparison of Helicobacter pylori in patients with endoscopic dyspepsia without mucosal lesions before and 6 
months after treatment based on age, sex, BMI, duration of dyspnea, family history of gastrointestinal malignancies, history 









Before 44 (74.6%) 15 (25.4%) 
0.157 
After 48 (81.4%) 11 (18.6%) 
50=< 
Before 47 (83.9%) 9 (16.1%) 
0.002 
After 53 (94.6%) 3 (5.4%) 
sex 
Male 
Before 45 (87.5%) 11 (19.6%) 
0.058 
After 49 (87.5%) 7 (12.5%) 
Female 
Before 46 (78%) 13 (22%) 
0.206 
After 52 (88.1%) 7 (11.9%) 
BMI 
<=25 
Before 47 (79.7%) 12 (20.3%) 
0.059 
After 52 (88.1%) 7 (11.9%) 
25< 
Before 44 (78.6%) 12 (21.4%) 
0.132 
After 49 (87.5%) 7 (12.5%) 
duration of dyspepsia 
(years) 
<=1 
Before 43 (84.3%) 8 (15.7%) 
0.005 
After 44 (86.3%) 7 (13.7%) 
1< 
Before 48 (75%) 16 (25%) 
0.013 
After 57 (89.1%) 7 (10.9%) 




Before 8 (80%) 2 (20%) 
1 
After 8 (80%) 2 (20%) 
No 
Before 83 (79%) 22 (21%) 
0.012 
After 93 (88.6%) 12 (11.4%) 
previous history of 
Helicobacter pylori 
Yes 
Before 27 (75%) 9 (25%) 
0.096 
After 32 (88.9%) 4 (11.1%) 
No 
Before 64 (81%) 15 (19%) 
0.096 
After 69 (87.3%) 10 (12.7%) 
history of smoking 
 
Yes 
Before 27 (75%) 9 (25%) 
0.317 
After 30 (83.3%) 6 (16.7%) 
No 
Before 64 (81%) 15 (19%) 
0.02 
After 71 (89.9%) 8 (10.1%) 
history of alcohol 
Yes 
Before 10 (83.3%) 2 (16.7%) 
0.317 
After 11 (91.7%) 1 (8.3%) 
No 
Before 81 (78.6%) 22 (21.4%) 
0.029 
After 90 (87.4%) 13 (12.6%) 
history of drug 
 
Yes 
Before 53 (82.8%) 11 (17.2%) 
0.414 
After 55 (85.9%) 9 (14.1%) 
No 
Before 38 (74.5%) 13 (25.5%) 
0.021 
After 46 (90.2%) 5 (9.8%) 
 
family history of gastrointestinal malignancies, 
negative history of H. pylori, negative history of 
smoking and not using alcohol, and lack of history of 
drug use among patients were effective on the 
decreasing rate of H. pylori after 6 months of 
treatment (p<0.05). However, age and BMI did not 
affect the decreasing rate of H. pylori after 6 months 
of treatment. Moreover, gender women, negative 
family history of gastrointestinal malignancies, and 
lack of history of using alcohol was effective on 
decreasing trend of chronic gastritis after 6 months of 
treatment (p<0.05). However, the age, BMI, duration 
of dyspepsia, history of H. pylori, history of smoking, 
and history of drug use among patients did not affect 
the reduction in the severity of chronic gastritis after 6 
months of treatment. 
Furthermore, gender women, BMI less than 25, 
duration of dyspepsia under 1 year, negative family 
history of gastrointestinal malignancies, negative 
history of H. pylori, lack of history of smoking and 
alcohol consumption, and negative history of drug use 
among patients were effective on decreasing metaplasia 
after 6 months of treatment (p<0.05). However, the age 
of patients did not affect the decreasing trend of  
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Table 6: Comparison of metaplasia in patients with endoscopic dyspepsia without mucosal lesions before and 6 months 
after treatment based on age, sex, BMI, duration of dyspnea, family history of gastrointestinal malignancies, history of 










Before 44 (74.6%) 15 (25.4%) 
0.021 
After 52 (88.1%) 7 (11.9%) 
50=< 
Before 33 (58.9%) 23 (41.1%) 
0.035 
After 40 (71.4%) 16 (28.6%) 
sex 
Male 
Before 43 (76.8%) 13 (23.2%) 
0.109 
After 49 (87.5%) 7 (12.5%) 
Female 
Before 34 (57.6%) 25 (42.4%) 
0.003 
After 43 (72.8%) 16 (27.2%) 
BMI 
<=25 
Before 38 (64.4%) 21 (35.6%) 
0.013 
After 47 (79.7%) 12 (20.3%) 
25< 
Before 39 (69.6%) 17 (30.4%) 
0.058 
After 45 (80.4%) 11 (19.6%) 
duration of dyspepsia 
(years) 
<=1 
Before 37 (72.5%) 14 (27.5%) 
0.414 
After 39 (76.5%) 12 (23.5%) 
1< 
Before 40 (62.5%) 24 (37.5%) 
0.002 
After 53 (82.8%) 11 (17.2%) 




Before 8 (80%) 2 (20%) 
0.564 
After 9 (90%) 1 (10%) 
No 
Before 69 (65.7%) 36 (34.3%) 
0.002 
After 83 (79%) 22 (21%) 
previous history of 
Helicobacter pylori 
Yes 
Before 22 (61.1%) 14 (38.9%) 
0.058 
After 28 (77.8%) 8 (22.2%) 
No 
Before 55 (69.6%) 24 (30.4%) 
0.013 
After 64 (81%) 15 (19%) 
history of smoking 
 
Yes 
Before 30 (83.3%) 6 (16.7%) 
0.317 
After 33 (91.7%) 3 (8.3%) 
No 
Before 47 (59.5%) 32 (40.5%) 
0.001 
After 59 (74.7%) 20 (25.3%) 
history of alcohol 
Yes 
Before 10 (83.3%) 2 (16.7%) 
0.317 
After 11 (91.7%) 1 (8.3%) 
No 
Before 67 (65%) 36 (35%) 
0.003 
After 81 (78.6%) 22 (21.4%) 
history of drug 
 
Yes 
Before 45 (70.3%) 19 (29.7%) 
0.083 
After 51 (79.7%) 13 (20.3%) 
No 
Before 32 (62.7%) 19 (37.3%) 
0.007 
After 41 (80.4%) 10 (19.6%) 
metaplasia after 6 months of treatment. 
Gender, negative family history of cancer, and 
negative alcohol use were three variables that 
improved all three biopsies pathology chronic 
gastritis, H. pylori, and metaplasia after 6 months with 
significant p value. Other variables had significant 
changes on one or two of these three pathologies after 
6 months of follow up. 
Based on the literature review conducted by the 
researchers in the present study, no study has been 
carried out using the method exploited in this study. Of 
course, it has been reported in many previous studies 
that PPI consumption can be effective in reducing 
dyspepsia symptoms20. In a study by Yalçin et al, 
according to the results similar to those obtained in the 
present study, it was found that the rate of recurrence of 
H. pylori infection decreased among patients with 
dyspepsia treated with H. pylori eradication based on 
the upper endoscopy after 6 months22. In a study by 
Kim et al, in results consistent with those of the present 
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study, gender and BMI were stated to be the predictive 
of the recovery of patients with dyspepsia after 1 year 
of H. pylori eradication therapy. However, the age of 
patients was not predictive of significance in line with 
the present study. Therefore, eradication of H. pylori 
was the only important factor in the recovery of 
patients with dyspepsia after one year23. Results of the 
study performed by Mansour-Ghanaei et al, were in 
agreement with the present study; these results 
indicated that the incidence rate of H. pylori infection 
based on endoscopy among patients with dyspepsia 
was decreased after 10 weeks and 1 year. In addition, 
the rate of recurrence of H. pylori was 5% after one 
year of treatment 24. In a study by Tirgar Fakheri et al 
in line with the results of the present study, it was 
revealed that the incidence of H. pylori based on 
endoscopy in patients with duodenal ulcer was 
reduced after 2 years of successful treatment as the 
present study. In spite of the successful initial 
treatment and eradication of H. pylori, recurrence rate 
of H. pylori infection is high. This can affect the 
treatment strategy and follow-up of patients25. In the 
study by Gunaid et al, in results similar to those 
obtained in the present study, the incidence rate of H. 
pylori infection based on endoscopy among patients 
with dyspepsia were treated with eradication was 
82.2% at the onset of treatment and the recurrence rate 
of H. pylori was 34% after one year. Of course, the 
recurrence rate of H. pylori is high after one year, 
which can be due to the large resistance of bacteria 
resulting from unlimited use of antibiotics26. In a study 
by Kamada et al, was in line with the present study, it 
was stated that the H. pylori rate was reduced and 
dyspeptic symptoms were improved after 3 years of 
H. pylori eradication treatment among patients with 
dyspepsia based on endoscopy27. In a study by 
Kyzekove et al, results of which were consistent with 
those of the present study, it was found that based on 
the endoscopy in patients with dyspepsia, there was a 
significant reduction in gastritis intensity and H. pylori 
levels after 6 months of treatment. However, there was 
no decrease in the metaplasia rate in contrast to the 
present study, hence, eradication therapy improved 
inflammatory changes and dyspepsia symptoms. The 
morphologic changes of the gastric mucosal lesions 
were significantly associated with dysmotility 
symptoms28. In the study by Goldstein, endoscopy was 
performed on 85 patients with metaplasia pathology 
and they were undergoing annual biopsy under follow-
up. Finally, it was concluded that sustained metaplasia 
remained only in 7% of cases consistent with the 
present study19. In the study by LEUNG in a 7-year 
investigation; it was revealed that the risk of 
progression of metaplasia to cancer has been reduced 
with H. pylori eradication. This study showed a 
significant relationship between metaplasia with age 
over 45 years in contrast to the present study and 
alcohol consumption similar to the present study29. In 
the study by Felley et al, regarding examination of the 
factors influencing the progression of cardiac 
metaplasia, there was no significant difference in terms 
of gender in the Mary Barrett group unlike the present 
study, which was higher among women; metaplasia was 
observed in 42% of patients. In this study, age, 
smoking, and BMI had a strong relationship with 
metaplasia similar to the present study; however, H. 
pylori, in contrast to the present study, did not show a 
significant relationship with GERD30. 
Being as a clinical trial was one of the strengths of this 
study, though the study was along with some 
limitations. These limitations included presence of few 
similar studies and the limited possibility of comparison 
of this study with other studies. Therefore, it is 
recommended that future studies similar to the present 
study be designed, relatively low sample size in this 
study and hence, the insignificant differences before 
and after treatment. Therefore, future studies are 
recommended to be designed with higher sample size. 
Unfortunately, despite attempting to examine all 
biopsies by one pathologist, due to the lack of access to 
him, some of the samples were reported by other 
pathologists. Due to the difficulty in coordinating the 
referral for second endoscopy, in some cases, intervals 
were less or more than six months. In addition, adequate 
information on the correct use of medications was not 
available. Finally, it seems that the severity of chronic 
gastritis, H. pylori rate, and metaplasia among patients 
with dyspepsia, endoscopy and without mucosal lesions 
decreased after 6 months of treatment compared to pre-
treatment. Moreover, gender, negative family history of 
gastrointestinal malignancies, and negative history of 
alcohol consumption in patients were associated with a 
reduction in the severity of chronic gastritis after 6 
months of treatment. Age, gender, BMI, duration of 
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dyspepsia, negative family history of gastrointestinal 
malignancies, negative history of H. pylori, negative 
history of smoking and alcohol, and no history of drug 
use of patients were effective on the H. pylori rate after 
6 months of treatment. Furthermore, gender, BMI, 
duration of dyspepsia, negative family history of 
gastrointestinal malignancies, no history of H. pylori, 
negative history of smoking and alcohol, and negative 
history of drug use were effective on the rate of 
metaplasia after 6 months of treatment. Regarding the 
number of chronic gastritis 103 cases H. pylori 24 
cases, and metaplasia 38 cases, respectively, report of 
a relatively benign pathology among patients with 
normal endoscopy, despite the absence of definitive 
endoscopic lesion, is routinely common. This 
sometimes imposes medical treatment costs and 
numerous supplementary procedures, many of which 
disappear in endoscopy follow-up and are not 
reported. Performing biopsy may be limited among 
patients with normal appearance, and only be 
conducted among a specific group with restricted risk 
factors. 
Conclusion 
Regarding the reduction in the severity of chronic 
gastritis, Helicobacter pylori and metaplasia in 
patients with endoscopic mucosal endoscopy after 6 
months of treatment, it is recommended that refraining 
from unnecessary follow-up and biopsy and imposing 
cost to the patient and the system of treatment and be 
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